BNTX vs. MTD: BioNTech vs. Mettler-Toledo Stock Comparison

November 11, 2026

How do BioNTech (BNTX) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BioNTech (BNTX) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BNTX is classified in Biotechnology while MTD is classified in Life Sciences Tools & Services.

Mettler-Toledo (MTD) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for BioNTech (BNTX) and Mettler-Toledo (MTD)
Profile Item	BNTX	MTD
Name	BioNTech SE American Depositary Share	Mettler-Toledo International Inc.
Country/Region	Germany	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	21.70 billion USD	34.25 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	October 10, 2019	November 14, 1997
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

BNTX

MTD

GSPC

BioNTech (BNTX) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for BioNTech (BNTX) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for BioNTech (BNTX) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BioNTech (BNTX) and Mettler-Toledo (MTD)
Metric	BNTX	MTD
Total Return (1Y)	-14.78%	21.58%
Total Return (3Y, Annualized)	-3.99%	19.54%
Total Return (5Y, Annualized)	-17.02%	2.36%

Risk Profile

Drawdown History

BNTX

MTD

GSPC

BioNTech (BNTX) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for BioNTech (BNTX) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BioNTech (BNTX) and Mettler-Toledo (MTD)
Metric	BNTX	MTD
Volatility (1Y, Annualized)	47.44%	31.70%
Beta (5Y)	1.30	1.15
Max Drawdown (5Y)	-78.10%	-43.47%
Avg. Volume (3M)	1.21M	197.80K

Risk-Adjusted Performance

Risk-Return Positioning

BNTX and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BioNTech (BNTX) and Mettler-Toledo (MTD)
Metric	BNTX	MTD
Sharpe Ratio (1Y)	-0.40	0.55
Sortino Ratio (1Y)	-0.59	0.75

Profitability

ROE (TTM)

Mettler-Toledo (MTD) has no ROE value reported for this period; BioNTech (BNTX) reports a negative figure of -8.14%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.14%

Max: 109.18%
Q3: 6.23%
BNTX: -8.14%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
MTD: --

BioNTech (BNTX) vs. Mettler-Toledo (MTD): MTD does not report ROE, so it has no value marker; BNTX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Mettler-Toledo (MTD) reports 22.25%, ranking against industry peers normally.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-60.87%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
BNTX: -60.87%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD: 22.25%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BioNTech (BNTX) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both BioNTech (BNTX) at 30.28% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.28%

Max: 83.12%
BNTX: 30.28%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max: 83.12%
MTD: 28.70%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BioNTech (BNTX) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BioNTech (BNTX) and Mettler-Toledo (MTD)
Metric	BNTX	MTD
ROE (TTM)	-8.14%	--
ROA (TTM)	-4.04%	20.09%
Net Margin (TTM)	-60.87%	22.25%
Operating Margin (TTM)	30.28%	28.70%
Gross Margin (TTM)	76.73%	59.16%

Growth

Revenue Growth

Both BioNTech (BNTX) at 4.32% and Mettler-Toledo (MTD) at 3.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

BioNTech (BNTX) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; BioNTech (BNTX) has no EPS growth figure this period.

BioNTech (BNTX) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for BioNTech (BNTX) and Mettler-Toledo (MTD)
Metric	BNTX	MTD
Revenue Growth (YoY)	4.32%	3.98%
Revenue Growth (3Y CAGR)	-45.06%	0.90%
EPS Growth (YoY)	--	3.88%
EPS Growth (3Y CAGR)	--	3.06%

Financial Strength

Current Ratio (MRQ)

BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.55

Max: 25.13
Q3: 12.13
BNTX: 8.55
Median: 5.52
Q1: 2.47
Min: 0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MTD: 1.10
Min: 0.10

BioNTech (BNTX) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

BioNTech (BNTX) at 0.02 keeps leverage in the lower quartile, while Mettler-Toledo (MTD) at 26.06 is above its industry debt-to-equity ratio range.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
BNTX: 0.02
Min: 0.00

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD: 26.06
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

BioNTech (BNTX) vs. Mettler-Toledo (MTD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BioNTech (BNTX) and Mettler-Toledo (MTD)
Metric	BNTX	MTD
Current Ratio (MRQ)	8.55	1.10
Debt / Equity (MRQ)	0.02	26.06
Net Debt / EBITDA	--	1.58

Dividends

Dividend Yield (TTM)

Neither BioNTech (BNTX) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BioNTech (BNTX) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BioNTech (BNTX) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BioNTech (BNTX) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BioNTech (BNTX) and Mettler-Toledo (MTD)
Metric	BNTX	MTD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Mettler-Toledo (MTD) trades at 37.38 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
BNTX: --

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max: 85.34
Q3: 43.46
MTD: 37.38
Median: 26.69
Q1: 13.30
Min: 0.07

BioNTech (BNTX) vs. Mettler-Toledo (MTD): BNTX does not report P/E ratio, so it has no value marker; MTD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both BioNTech (BNTX) at 8.96 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.96

Max: 58.18
Q3: 25.77
BNTX: 8.96
Median: 7.30
Q1: 3.01
Min: 0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 58.18
Q3: 25.77
MTD: 8.16
Median: 7.30
Q1: 3.01
Min: 0.01

BioNTech (BNTX) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile relative to book while Mettler-Toledo (MTD) at 442.71 prices above its industry range — a wide valuation gap against assets.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.09

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
BNTX: 1.09
Min: -5.59

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD: 442.71
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

BioNTech (BNTX) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BioNTech (BNTX) and Mettler-Toledo (MTD)
Metric	BNTX	MTD
P/E Ratio (TTM)	--	37.38
P/S Ratio (TTM)	8.96	8.16
P/B Ratio (MRQ)	1.09	442.71
Free Cash Flow Yield (TTM)	-7.34%	1.97%